| 【Company Research】I-Mab BioPharma (IMAB US) – Lemzoparlimab showed encouraging data on MDS |
| 【Company Research】Innovent Biologics (1801 HK) – Expanding portfolio of commercial products |
| 【Company Research】SANY International (631 HK) – Post-results and NDR takeaways: Expect a strong year in 2022E |
| 【Company Research】Nayuki Holdings Limited (2150 HK) – Looking forward to the digitalization in FY22E |
| 【Company Research】JS Global Lifestyle (1691 HK) – Uninspiring guidance and a cheap valuation |
| 【Company Research】BYD Electronics (285 HK) – Margin pressure remains an overhang; Maintain HOLD |
| 【Company Research】Sunac Services (1516 HK) – Very attractive risk/reward after earnings outlook reset; Maintain Buy |
| 【Company Research】Chinasoft (354 HK) – Strong demand despite near-term margin pressure |
| 【Company Research】China Construction Bank (939 HK) – FY21 review: results in line, expecting stable asset quality in 2022 |
| 【Company Research】Tongda Group (698 HK) – Emerging growth drivers to fuel recovery in 2H22E |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
